Capsule Summary Slidesets

Share

Program Content

Activities

  • ARROW: BLU-667 for <i>RET</i>+ NSCLC
    ARROW: Phase I Trial of BLU-667, a Novel RET Inhibitor, in Patients With Advanced RET Fusion–Positive NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2019

    Expires: June 02, 2020

  • AMG 510 in <i>KRAS</i><sup>G12C</sup>+ Tumors
    Phase I Study of AMG 510, a Novel KRASG12C Inhibitor, in Advanced KRASG12C-Positive Solid Tumors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2019

    Expires: June 03, 2020

  • ICIs in NSCLC With Autoimmune Disease
    Real-World Outcomes With Immune Checkpoint Inhibitors in Patients With Advanced NSCLC and Autoimmune Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2019

    Expires: June 04, 2020

  • TAK-788 in <i>EGFR</i> Ex20 Mut NSCLC
    Phase I/II Study of TAK-788, an Investigational EGFR/HER2 TKI, in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertions
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2019

    Expires: June 09, 2020

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro